FDA and FTC warn Mahita/PushMyCart over unapproved Ayurvedic/homeopathic COVID-19 treatment claims.
What happened
FDA reviewed the website on August 2, 2021, and FTC reviewed it on August 16, 2021; FDA also reviewed the company’s Facebook page and Amazon storefront. FDA found the company offered Patanjali Coronil Kit, arsenic album dilutions, and Balarishtam products for sale in the U.S. with claims that they mitigate, prevent, treat, diagnose, or cure COVID-19. FDA called them unapproved new drugs and misbranded drugs.
What FDA found
The company sold products as drugs for COVID-19 without FDA approval.
FD&C Act section 505(a), 21 U.S.C. § 355(a)The products’ labeling and promotions misbranded them.
FD&C Act section 502, 21 U.S.C. § 352The company introduced or delivered these products into interstate commerce, which is prohibited.
FD&C Act sections 301(a) and (d), 21 U.S.C. § 331(a) and (d)The company advertised that the products can prevent, treat, or cure COVID-19 without competent and reliable scientific evidence.
FTC Act, 15 U.S.C. 41 et seq.
What FDA wants
FDA tells the company to immediately stop selling the unapproved COVID-19 products and, within 48 hours, email FDA with the steps taken and documentation to prevent repeat violations. FTC also requires a 48-hour email certifying that the unsubstantiated claims have stopped.
Who should pay attention
- online sellers of Ayurvedic or homeopathic products
- marketplaces hosting third-party product listings
- companies making disease-treatment claims in ads
This is a summary. Read the original letter on fda.gov.